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Abstract
Background: Biobanks are considered to be key infrastructures for research development and have generated a
lot of debate about their ethical, legal and social implications (ELSI). While the focus has been on human genomic
research, rapid advances in human microbiome research further complicate the debate.
Discussion: We draw on two cystic fibrosis biobanks in Toronto, Canada, to illustrate our points. The biobanks have
been established to facilitate sample and data sharing for research into the link between disease progression and
microbial dynamics in the lungs of pediatric and adult patients. We begin by providing an overview of some of the
ELSI associated with human microbiome research, particularly on the implications for the broader society. We then
discuss ethical considerations regarding the identifiability of samples biobanked for human microbiome research,
and examine the issue of return of results and incidental findings. We argue that, for the purposes of research
ethics oversight, human microbiome research samples should be treated with the same privacy considerations
as human tissues samples. We also suggest that returning individual microbiome-related findings could provide
a powerful clinical tool for care management, but highlight the need for a more grounded understanding of
contextual factors that may be unique to human microbiome research.
Conclusions: We revisit the ELSI of biobanking and consider the impact that human microbiome research might
have. Our discussion focuses on identifiability of human microbiome research samples, and return of research
results and incidental findings for clinical management.
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Background
Literature on biobanks has mainly focused on human
genetics and genomics, with many ethical challenges
remaining unresolved [1, 2]. Rapid advances in human
microbiome research can further complicate matters.
This field of research aims to elucidate the role of bacteria
and other microbes in different areas of our body in health
maintenance and disease development. In this paper, we
discuss the ethical, legal and social implications (ELSI)
related to biobanking for human microbiome research.
We draw on two cystic fibrosis (CF) biobanks located in
Toronto, Canada, to illustrate our points where applicable:
the Toronto CF lung microbiome biobank housed at the
Toronto General Hospital and the CF sputum biobank at
the Hospital for Sick Children. We focus specifically on: 1)
ethical considerations of categorization and identifiability
of samples biobanked for human microbiome research;
and 2) clinical actionability of human microbiome re-
search and ethical challenges associated with returning in-
dividual research results and incidental findings.
CF is a common fatal genetic disease among individuals
of European backgrounds, with an estimated frequency of
about 1 in 2500 live births [3]. Patients experience progres-
sive deterioration of pulmonary function and eventually
death due to recurrent microbial infections of the respira-
tory tracts. Although substantial advances in clinical care
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and antibiotic treatments have increased life expectancy
over the past few decades, with the median survival age in
Canada currently at 49 years [4], patient health deteriorates
in spite of seemingly appropriate treatments. The two CF
biobanks have been established as publicly available reposi-
tories to facilitate sample and data sharing for research into
CF progression, including characterizing the diversity and
dynamics of the microbial communities in the lungs of
pediatric and adult patients. The long-term goal is to facili-
tate the development of effective and tailored treatments
that can control lung infections.
We begin by providing an overview regarding some
of the ELSI of human microbiome research. Given that
the human microbiome can be changed by personal
lifestyle and environmental conditions, there has been
considerable scientific and public interest in the modifi-
cation of the human microbiome for health and disease
management. However, modifying the human micro-
biome for health-related reasons may have social and
ethical implications for the individuals, their family
members and even broader communities. We then ex-
plore the implications of human microbiome research for
the conceptualization of the human being and human
identity, and outline ethical considerations regarding the
identifiability of samples biobanked for human micro-
biome research (e.g., sputum). We propose that samples
collected from microbiome research participants should
be treated with the same privacy and confidentiality safe-
guards as human tissue samples and other identifying
sources of information. We refer to such samples as hu-
man microbiome research samples, which we differentiate
from bacterial cultures that consist of bacterial strains iso-
lated from these samples, grown in the laboratory, and
cannot be linked back to the donors. Finally, we examine
the issue of return of research results and incidental
findings for human microbiome research in general,
and for disease-specific biobanks, such as the CF bio-
banks, in particular. We suggest that the return of indi-
vidual findings could provide a powerful clinical tool
for care management as the dynamic nature of the
human microbiome may offer substantial opportunity
for intervention and health modulation. We outline the
ethical challenges associated with returning individual
findings and highlight the need for a more grounded
understanding of contextual factors that may be unique
to human microbiome research.
Overview of human microbiome research
The Human Microbiome Project (HMP) was launched by
the U.S. National Institutes of Health in 2007, and in-
cluded a number of member organizations and repositor-
ies connecting to a central data repository known as the
Data Analysis and Coordination Center (DACC). A central
aim has been to characterize a “core” human microbiome,
using healthy adult cohorts, that is common to all or a
vast majority of humans across several body regions,
including the nasal passages, oral cavity, skin, gastro-
intestinal tract and urogenital tract [5, 6]. Findings
about the high variability of microbial composition
across individuals and across body sites within an indi-
vidual have led to further research into the stability of
the human microbiome over time and the effects of
environment on its composition. While the initiative
has produced valuable scientific knowledge, some HMP
researchers have questioned the representativeness of
the sample populations and what it means to be “normal”
and “healthy” [7]. The extensive sampling with Euro-
Americans of middle to upper socioeconomic status
has raised social justice concerns that science may be
more prepared to develop interventions with this group
than other social groups [8]. It also raises the question
of how the HMP may be ethically promoted to under-
served populations, who may have high hopes for
therapeutic benefits or are vulnerable to commercial
exploitation.
There has been a surge of basic and translational
research to investigate the mechanisms of the human
microbiome and how it may be modulated to improve
health and avoid disease. Most research efforts have
focused on the vital functions of the gut microbiota in
the maintenance of homeostasis in the body, with
promising insights into the etiology, diagnosis and
treatment of various health problems, including gastro-
intestinal diseases, colon cancer, types 2 diabetes and
obesity [9–11]. In the human gut, the resident microbes
carry out an array of metabolic activities that are distinct
from those encoded by the human genome but are essen-
tial for bodily functioning. These metabolic activities have
major consequences that can be beneficial or harmful.
Gut microbes help break down nondigestible dietary
products and contribute nutrients and energy to the hu-
man body [9]. A balance is thus maintained with the hu-
man host’s metabolism and immune system. A disruption
in the gut microbiota can lead to inflammation and infec-
tion, and contribute to the development of gastrointestinal
diseases and possibly diabetes and obesity. Translational
research efforts have begun to explore alternative inter-
ventions for treating gastrointestinal and other types of
disease, which emphasize the maintenance of a healthy
microbiome rather than the eradication of bacteria by
antibiotics. These include the use of diets [12, 13], probio-
tics and prebiotics [14–16], and microbial ecosystem ther-
apeutics [17].
Advances in human microbiome research have raised
high hopes about potential medical applications along
with cautions about scientific validity, clinical utility,
and social and ethical challenges. Many of the prevailing
ethical issues in human microbiome research overlap with
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those in human genetic research. The ELSI literature on
human microbiome research has largely focused on in-
formed consent mechanisms, return of research results
and incidental findings to participants, data sharing, priv-
acy and confidentiality, ownership of samples and benefit
sharing which have implications for social justice issues
[7, 18–21]. There has been limited study into broader
ELSI with regard to the public impact of human micro-
biome research. For example, Slashinski et al. examined
investigator perspectives on the commercialization of
human microbiome research [22]. Their study raised
concerns over how the scientific value of research into
the human microbiome and health is mobilized by the
marketplace to promote the consumption of probiotics
and dietary supplements, despite a lack of regulation
and knowledge about the safety and effectiveness of
these products. The authors suggested “the need to find
a balance between the marketplace, scientific research,
and the public’s health” [p.1].
Efforts to translate human microbiome research into
new medical applications and technologies create im-
portant opportunities and challenges scientifically and
socially. The knowledge that an individual’s microbiome
can be modified by personal lifestyle and environmental
conditions is leading to promising health interventions,
as well as concerns about the social and ethical implica-
tions of such purposeful modification. Sonnenburg and
Fischbach discussed therapeutic opportunities created by
manipulating the human microbiome, such as through
probiotics, prebiotics, and small-molecule and bio-
logical drugs [23]. The application of diets and probio-
tics to improve health and manage disease has captured
considerable attention from the public, especially for
gastrointestinal diseases. However, a review of online
dietary recommendations and popular dietary regimes
for inflammatory bowel disease found conflicting infor-
mation and a lack of evidence-based guidelines [24].
Furthermore, probiotics are classified as food or dietary
supplements and do not undergo a vigorous regulatory
evaluation, which can result in variable product quality
and unsubstantiated claims about their therapeutic
benefits [23]. Petrof et al. examined the application of
microbial ecosystem therapeutics, including fecal trans-
plants and synthetic stool, to restore a patient’s dis-
rupted gut microbiota [17]. Fecal transplants involve
introducing the stool from a healthy donor into the
gastrointestinal tract or colon of the patient, and have
been reported to be a successful treatment for Clostridium
difficile infection (CDI) and gastrointestinal diseases
[17, 25–27]. However, the treatment has not gained
traction in medical institutions, which could be due to
a lack of knowledge about safety and long-term outcomes.
There have also been suggestions about the treatment’s
unappealing nature as a barrier to its uptake. In Canadian
media, fecal transplants have often been portrayed as be-
ing inherently disgusting [28]. Termed the “ick factor,” the
allegedly disgusting nature of the treatment is used to con-
struct different messages about its social acceptability and
status as a legitimate treatment. CDI and gastrointestinal
diseases pose significant economic and social burdens to
affected patients, their families, and health care systems in
many developed countries. In Canada, regulatory clarity
surrounding fecal transplants had been lacking for many
years. It was not until March of 2015 that Health Canada
drafted a guidance document to classify fecal transplants
as a biological drug and approve its use for the treatment
of CDI not responsive to conventional therapies [29]. Use
for other medical conditions is still under the regulations
of an investigational clinical trial. The case examples of
probiotics and fecal transplants illustrate the need to
examine public understandings of and commercial inter-
ests in human microbiome research and related medical
applications.
O’Doherty, Virani, and Wilcox have argued that social
and ethical implications may arise from technologies to
modify the human microbiome, which can go beyond
the individuals [30]. The composition and diversity of
the human microbiome can change as a result of life-
styles and environmental conditions that are associated
with broader sociocultural practices. Societal shifts to a
more sedentary lifestyle and an industrialized diet rich in
animal proteins, fats and simple carbohydrates in Western
countries have a negative impact on the gut microbiota
diversity [12, 13, 31]. A Westernized diet has been asso-
ciated with increasing risks of developing obesity,
gastrointestinal diseases, cardiovascular disease and colon
cancer. Moreover, there is evidence that the microbiota
compositions at different body sites are similar between
family members and people in regular close contact [32,
33], suggesting that microbiomes can be transmitted and
shared between individuals. Interestingly, a recent experi-
mental study found that a reduction in gut microbiota
diversity was also observed for the housemates of partici-
pants who took amoxicillin or azithromycin, two com-
monly prescribed antibiotics [34].
The notion that changes in the human microbiome
can be affected by other individuals raise important
social and ethical considerations. At an individual level,
questions arise about the impact that an individual’s
decision to modify his or her own microbiome may
have on other individuals with important implications
for autonomy [30]. Potentially, an individual’s micro-
biome may be affected by the health decisions of others
without his or her awareness. At a societal level, there
are public health implications if a large number of indi-
viduals adopt a health practice to change their micro-
biomes. With rapid advances in human microbiome
research, it is also conceivable to design public health
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initiatives that involve the purposeful modification of
the human microbiome to yield health benefits to the
broader society. Such large-scale initiatives might by-
pass individual health decision-making and bring about
unanticipated and long-term consequences of changing
the microbiomes of many individuals in a community
(See O’Doherty et al. for more details on public health
implications of technologies developed on the basis of
human microbiome research) [30].
In the sections below, we focus our discussion on the
ethical implications of biobanking for human microbiome
research that can have profound impact on the individ-
uals. In particular, we provide a detailed discussion with
regard to whether microbiome-related data can provide
additional information that is personal and sensitive be-
yond genetic data and the potential of returning research
findings for clinical care.
Categorization and identifiability of the human microbiome
In this section, we focus on ethical issues associated
with categorizing human microbiome research samples
and the debate over whether the human microbiome
can provide uniquely identifying information. Advances
in human microbiome research have been argued from
an ecological and evolutionary perspective to have
dramatic implications for how we should conceptualize
the human being. Dethlefsen, McFall-Ngai, and Relman
explored the human-microbe symbiotic relationship
and how microbes and their human hosts have co-
evolved and selected for mutualistic interactions that
are essential for human health [35]. It has been argued
that humans are complex “superorganisms” who pos-
sess an “extended genome” of millions of microbial
genes [10]. Rhodes asserted that the concept of humans
as “superorganisms” recasts the view of humans from
“atomistic individual organisms” to “an amalgam of us
and them,” and “our coexistence with the microbiome
tells us that human evolution is not just human history”
([36], p.2). O’Hara and Shanahan described the gut
microbiota as a “forgotten organ” given that it has “a
metabolic activity equal to a virtual organ within an
organ” ([37], p.688). Sonnenburg and Fischbach also
stated that “our microbiota is more like an organ than
an accessory: These microbes are not just key contribu-
tors to human health but a fundamental component of
human physiology” ([23], p.1).
Despite scientific conceptualizations of human beings
as superorganisms, it is difficult to determine the up-
take of this perspective in our sense of self in everyday
life. Gligorov and colleagues argued that, to the extent
that it permeates everyday life, scientific knowledge of
the human microbiome may have an impact on how we
think of ourselves and how we perceive ourselves in
relation to the environment and other people, which
can influence our sense of moral responsibilities and behav-
iors [38]. They pointed to the shifts in the conceptualization
of the human self that have stemmed from past scientific
discoveries. These include the discoveries that mental
activities are located in the brain and the existence of
neurotransmitters, and the mapping of the human gen-
ome and association of DNA with human traits and men-
tal illnesses. Messages about the human body/microbe
ecosystem have become more accessible to the public in
recent years through the media. Nerlich and Hellsten
suggested that metaphorical framings in the media since
2003 onwards have personified microbes as having a
quasi-human agency and emphasized the interactions
between microbes and between microbes and humans
[39]. In these media framings, microbes are no longer
conceptualized solely as enemies and a danger to health
but also friends and healers. Humans are also framed as
hybrids that blur the boundaries between the human self
and microbes.
From a bioethical perspective in the context of re-
search and biobanking, it is currently not clear whether
the human microbiome should be categorized as part
of or separate from the human body [18]. Similar to
some samples collected and biobanked for human gen-
etic and other research purposes, some types of samples
biobanked for human microbiome research might
otherwise be considered waste (e.g., dead skin, feces,
saliva). In the case of the Toronto CF lung microbiome
biobank, sputum samples from the St. Michael’s Hos-
pital Adult CF Clinic are collected from adult patients
who have consented to participating in the Toronto CF
Lung Microbiome Team’s study and to providing an
extra sputum sample at each clinic visit. This sample is
collected in addition to those provided as part of
routine clinical care. In contrast, pediatric CF sputum
samples collected at the Hospital for Sick Children
represent excess material from specimens collected for
routine microbiologic testing, which would otherwise
have been discarded following completion of testing.
Assent from pediatric patients and consent from par-
ents are obtained for biobanking the excess material for
research purposes.
The fact that there are opportunistic bacteria and other
microbes which are harmful, and potentially fatal, forms
the ontological basis for the traditional view of microbes
as pathogens and inimical intruders separated from the
human body. On the other hand, it could also be argued
from an ecological and evolutionary perspective that the
human microbiome is part of the human being due to the
co-evolution of humans and microbes and the vital bodily
functions performed by microbes. The description of the
gut microbiota as an “organ” situates the gut microbial
communities collectively as part of the human body. It
could, thus, be argued that samples collected for human
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microbiome research should be treated as human tissue
samples (e.g., tumours and blood).
In addition to microbes, human microbiome research
samples generally contain human cells and/or DNA.
The HMP has stipulated that metagenomic data are
deposited into a public open-access database while
potentially identifying data (e.g., clinical data, human
DNA data) are placed in a controlled-access database
[40]. An interview study with HMP investigators re-
ported that, although some investigators felt that par-
ticipants’ privacy and confidentiality were protected,
others expressed concerns over the inadvertent release
of human DNA to the public database as a result of
inadequate filtering methods, computational limita-
tions, or unmapped portions of the human genome
[20]. Improvements in filtering methods and new un-
derstandings of the human genome can mitigate the
concern about human DNA data contamination in
metagenomic data. However, the issue that human
microbiome research samples contain human DNA still
raises concerns about privacy and confidentiality since
these samples can be analyzed in ways that are identifi-
able. In this respect, we suggest that human micro-
biome research samples should be treated by biobanks
with the same safeguards in terms of privacy and confi-
dentiality as any other human tissue samples or identifying
sources of information. However, we draw attention to cir-
cumstances where researchers obtain samples from a bio-
bank to culture bacteria for research purposes without
having any contact with the donors. If the bacterial cul-
tures exist separately from donor samples and cannot be
linked back to the donors, then a strong argument can be
made for not considering bacterial cultures that consist of
specific bacterial strains isolated from donor samples and
grown in the laboratory to be “human” samples.
Wolf et al. used the term, “biobank research system,”
to illustrate the relationship between three entities: 1)
primary researchers or collection sites feeding data and
samples into the biobank; 2) the biobank, with some
biobanks collecting and analyzing data/samples them-
selves; and 3) secondary researchers accessing data/
samples from the biobank for further research [41]. Ar-
guably, a biobank for human microbiome research has
the management responsibility to ensure that secondary
researchers who receive the coded data and/or samples
cannot readily re-identify the subjects, if the design of
the biobank has been established to maintain the possi-
bility of re-identification. Samples and data may have
already been de-identified by the primary researchers
or collection sites prior to being sent to the biobank.
The two Toronto CF biobanks and accompanying data-
base of clinical metadata are subject to management
regulations that are common practices across many
biobanks. According to Petersen and Van Ness, some
centralized biobanks do not retain identifiers or contact
information of donors to both protect privacy and avoid
the consideration of returning research results [42].
Since the long-term goal of the CF biobanks is to facili-
tate the development of tailored treatments that can
control lung infections, they have been set up to retain
the possibility of re-identification of patients and link-
age to clinical data. All specimens are identified only by
arbitrarily assigned patient study ID and specimen ID
numbers. Patient identity (including identifiers such as
medical record numbers) for each study ID number is
known only to the clinic coordinators who interact with
patients during clinic visits, and to the principal investi-
gators who oversee specimen collection at each site.
Any other investigators are able to access only the
study and specimen ID numbers. Occasional situations
have arisen necessitating re-identification of specific
patients, usually relating to the need to link study ID
numbers for patients whose clinical care has been
transferred from the pediatric CF clinic (Hospital for
Sick Children) to the adult CF clinic (St. Michael’s Hos-
pital), or to link sputum samples to de-identified lung
tissue obtained from the same patient following lung
transplantation (Toronto General Hospital). In such
situations, the initial study ID is submitted to the
principal investigator overseeing specimen collection at
the originating clinic, who then communicates patient
identity directly (and only) with the principal investiga-
tor for the receiving clinic or lung transplant program.
The receiving principal investigator links the patient
identity to the appropriate study ID number and com-
municates only the study ID number to secondary
investigator(s) requesting the linkage, who are then able
to use the additional study ID numbers to access add-
itional specimens and/or clinical data.
At present, there is a lack of scientific consensus over
whether microbiome-related data is uniquely identify-
ing like human genetic data. There have been some re-
search findings that suggest the potential of these data
to identify group affiliation and more personal informa-
tion. Arumugam et al. identified three enterotypes or
clusters of human gut microbiome based on the clus-
tering of key bacterial genera from 39 samples involving
six nationalities and including 22 sequenced fecal meta-
genomes of European individuals [43]. Sequencing of
dental plaque and saliva samples from 192 participants of
four ethnicities in the United States (African, Caucasian,
Chinese, and Latino) found ethnic-specific clustering of
microbial communities [44]. However, Jeffery, Claesson,
O’Toole and Shanahan commented that there is consider-
able debate about, and blurring of, the notion of distinct
enterotypes of the gut microbiota, and such categorization
may have oversimplified the complexity [45]. At an indi-
vidual level, it has been reported that skin-associated
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bacteria recovered from the surfaces of computer key-
boards and mice could be used as microbial “fingerprints”
to identify the individuals, and microbial fingerprint ana-
lysis could present a valuable resource for forensic identifi-
cation [46]. However, it is difficult to evaluate the practical
utility of information from microbial fingerprints giving
that the human microbiome is subject to modification by
lifestyles and environmental factors. The scientific uncer-
tainty over the stability of the microbiome raises questions
about whether microbial fingerprints can still be linked to
an individual after a certain amount of time [18].
It is possible that the information gleaned from an in-
dividual’s microbial profile at a specific point is not
identifying at a later point in time. However, this does
not preclude the possibility of microbial profiles being
combined with genetic and other types of information
in ways that are more personally revealing, such as pro-
viding additional information about past exposures,
visits to other countries, predisposition to certain con-
ditions, sexual practices, diet, and consumption of to-
bacco, alcohol and other drugs. The information could
potentially be used in ways that are detrimental to the
persons involved. Hoffmann et al. have raised the issue
that both human genetic and human microbiome re-
search may bring into existence new group stigmas that
are unknown to researchers or individuals prior to par-
ticipation in the research [7]. Of concern is whether
existing laws and regulations, such as the Personal
Information Protection and Electronic Documents Act
(PIPEDA) in Canada or the Genetic Information Non-
discrimination Act (GINA) in the U.S.A., are adequate
and sufficient to protect individuals or groups from
stigmatization and discrimination based on information
from their microbiome.
Return of individual research results and incidental
findings
Despite significant advances in human microbiome re-
search, there is limited understanding of the practical
and clinical relevance of most research findings to date.
Knowledge of an individual’s microbial profile could po-
tentially open up more decision points for diagnosis,
treatment, and risk management [18]. Unlike the human
genome which remains relatively static throughout an
individual’s life, the dynamic nature of the human micro-
biome could provide substantial opportunity for inter-
vention and microbial data could be more clinically
actionable than human genetic data. The translation of
human microbiome research into practical approaches
for diagnosis and treatment has generated extensive inter-
est in the scientific community. Zakutar and colleagues
demonstrated that analysis of the gut microbiome could
potentially be used with other known clinical risk factors
as a screening tool to improve early detection of colorectal
cancer [47]. Dominguez-Bello et al. conducted a pilot
study in which four newborns delivered by caesarean
section were exposed to maternal vaginal fluids at birth
[48]. They found that the gut, oral, and skin microbial
communities of these newborns were enriched and
comparable to vaginally delivered babies. Although the
long-term health effects are unknown, the study dem-
onstrates the potential to restore vaginal microbes in
C-section delivered newborns, who are at a higher risk
of developing obesity, asthma, allergies and other im-
mune deficiencies. In CF patients, Pseudomonas aerugi-
nosa and species of the Burkholderia cepacia complex
(BCC) are among the most common bacterial pathogens
isolated from lung infections. They are often implicated in
acute episodes of respiratory decompensation and in ac-
celeration of pulmonary deterioration. Coburn et al. found
that microbial diversity and lung function are greater in
pediatric patients and lower in older age groups, with
lower diversity correlates with worse lung function [49].
Hampton et al. also reported that microbial diversity is
greater in pediatric patients and microbial communities in
pediatric patients living together are more alike than those
living apart [50]. They proposed that, since the environ-
ment appears to be an important determinant of the
microbiota in pediatric patients, early intervention to
maintain or enhance its diversity may hold promise for
slowing disease progression. Effective intervention and
disease management require a clearer understanding of
how the airway microbial communities in CF patients
evolve and how they are influenced by repeated antibiotic
treatments and other environmental factors.
For CF patients with end-stage lung disease, lung trans-
plantation offers the only viable option. But a relatively
scarce supply of donor organs limits its availability. Many
transplant centers exclude patients with BCC infection
from the waiting list since they are at a greater risk for
post-transplant complications and have a higher mortality
rate than patients without the infection. More recent stud-
ies have indicated that the impact of BCC infection varies
by different species and strains. Patients with BCC infec-
tion were regularly transplanted at the Duke University
Medical Center in Durham, US, until 2002 [51]. A retro-
spective review of 75 patients undergoing lung transplant-
ation from 1992 to 2002 at the center indicated that the 1-
year and 5-year survival rates of patients infected with the
B. cenocepacia species were significantly lower compared
to patients infected with other BCC species and non-
infected patients. Likewise, a retrospective review of the
lung transplantation database at the Freeman Hospital,
UK, from 1989 to 2010 found that patients with B. cenoce-
pacia infection had significantly higher post-transplant
mortality rate, resulting in the center no longer accepting
patients with this condition on the waiting list [52]. The
Toronto Lung Transplant Program is a notable exception
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for not excluding patients with BCC infection. At present,
microbial sequencing poses no risk to patients enrolled in
the program in terms of being disqualified for lung trans-
plantation as a result of bacterial detection in their sam-
ples. However, questions regarding ethical obligations in
similar situations could arise if individual research results
or unexpected incidental findings could potentially lead to
significant alterations in disease management.
The bioethics literature is rich with debate about the
ethical obligations of researchers, if any, to disclose re-
search results or incidental findings and how disclosure
should be managed. Generally speaking, offering to return
aggregated research results to participants is considered to
be an ethical research practice. More controversial is the
issue of whether participants should receive feedback on
their individual data. The debate over returning individual
findings has mainly focused on human genetic and human
genomic research. Bredenoord et al. asserted that the
majority of perspectives in the literature on returning
individual genetic results advocate for either a very re-
strictive disclosure, wherein individual results should not
be returned except for life-saving data, or an intermediate
position of qualified disclosure, which holds that results
should be disclosed if they meet particular conditions [53].
The authors suggested that, rather than focusing on
whether research results should be returned, the debate
should address how to strike a balance between the bene-
fits and harms of disclosure and the appropriate proce-
dures for deciding.
Defining the criteria for returning research results re-
mains a matter of debate and may vary with research
contexts. Burke, Evans, and Jarvik indicated that efforts
should be made to clarify the criteria for returning re-
sults, appropriate caveats, and appropriate referrals if
the information is clinically relevant [54]. Likewise,
Rahimzadeh and colleagues argued for the need to
recognize contextual factors in determining the return
of incidental findings in pediatric oncology genetic re-
search [55]. Their interview study with 16 investigators
identified four key considerations for determining when
and under what circumstances to return. These include
1) clinical significance of results with clinical action-
ability being one of the foremost reasons for disclosure;
2) respect for individuals; 3) scope of professional respon-
sibilities and the need to take into account researcher/
clinician expertise and potential for liability; and 4) im-
plications for the healthcare/research system including
funding duration, resource constraints, and availability
of professional expertise such as genetic counselling.
According to Rahimzadeh et al., a one-size-fits-all ap-
proach may risk overlooking relevant contextual factors.
The role that biobanks may play in human micro-
biome research is still unclear due to the relative infancy
of the field and the lack of regulations regarding biobank
management and governance [56]. In the context of
human genomic research, Wolf et al. recommended that,
rather than placing all the responsibilities on primary
researchers or collection sites, biobanks have significant
responsibilities for the planning and management of re-
turn of research results and incidental findings [41]. The
authors suggested that findings that are analytically valid,
reveal an established and substantial risk of a serious
health condition, and are clinically actionable, should
be returned to consenting participants. As such, the co-
ordination and allocation of responsibilities between
the biobanks, primary researchers/collection sites, and
secondary researchers should be made explicit. Man-
aging return of results would require resources and
appropriate processes to realize the benefits of disclos-
ure without impairing the primary scientific purpose of
biobanks [41, 42]. These include dedicated personnel,
clinical expertise and clinical referral information, and
resources to securely maintain identifying and follow-
up contact information. Many questions remain about
the practicality and cost constraints of returning indi-
vidual results.
Clinical significance and actionability of human microbiome
research
In human microbiome research, concerns have been
raised that data may be interpreted prematurely or
incorrectly [7, 18–20]. Typically, before research find-
ings can be used in clinical care, further establishment
of scientific validity, reliability, and clinical significance
is needed. Presently, sequencing of sputum samples at
the two CF biobanks often occurs long after sample
collection and the impact of microbiome-related data
on clinical outcomes is almost completely unknown.
This does not, however, preclude the possibility that re-
search or incidental findings could be clinically action-
able in the future. It has been suggested that effective
early intervention to maintain or enhance the microbial
diversity of CF pediatric patients may improve health
and slow disease progression [50]. Therefore, the return
of individual microbiome findings could provide a power-
ful clinical tool for CF patient care management. However,
a necessary condition for the return of individual results is
that data can be linked back to a specific participant.
Effective translation of research into clinical care also
requires the flow of information between the biobank,
primary and secondary researchers, and the clinical team,
which may potentially increase the risks to privacy and
confidentiality. For disease-specific biobanks like the CF
biobanks, a communication plan should be established
with secondary researchers in the event that research or
unexpected incidental findings are significant for clinical
care, or the plan can be included in the Material and Data
Access Agreement. The biobanks will need appropriate
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procedures in place to deal with re-identification, if
they engage in the processes of disclosure, and have the
appropriate consultation and policy-making capacity to
determine under what circumstances to return and
what evaluation criteria should be used to make the
decision [41].
The questions of whether, how, and under what
contexts to return research or incidental findings have
led to much discussion in both human genetic and
human microbiome research [7, 18–20]. The lack of
knowledge about the clinical significance of most re-
search findings proves to be challenging for disclosure,
which can cause psychological or social harm if findings
are misinterpreted or inadequately interpreted. The
possibility of returning individual results also raises
questions of whether and how this should be addressed
in the consent processes in a way that participants can
understand without overstating the benefits of participa-
tion or raising false expectations of therapeutic benefits.
Moreover, in human microbiome research, incidental
findings of asymptomatic or subclinical infectious disease
raise not only the need for disclosure to participants, but
potentially to public health authorities and other people
who may be affected [7, 19]. This is complicated by the
issue that clinical manifestation may depend on a number
of factors, including interactions between the infecting
species with other microbes and the immune system, gen-
etics, age, and lifestyles. Hoffman and colleagues asked the
following questions: “Should the disclosure determination
be based on clinically significant findings even if the indi-
vidual is asymptomatic of the condition found? If so, do
we know what constitutes clinically significant path-
ology in terms of our microbiome?” ([7], p. 466). Know-
ledge of being at risk of developing a serious health
condition could cause anxiety and distress, especially if
there is no known cure or treatment. It could also lead
to adverse social consequences. In bioethics, the
principle of non-maleficence requires researchers to
not create unnecessary harm or injury, either through
acts of commission or omission. The unclear delineation
between bacterial colonization and infection poses the eth-
ical dilemma of assessing under what circumstances and to
whom to disclose, which requires a careful balance of the
potential benefits and harms of disclosing compared to not
disclosing.
In human genetics and human genomics, it has been
recommended that research results and incidental find-
ings that are analytically valid, clinically significant and
actionable should be returned to participants who have
consented to receiving research findings [41, 55]. While
these recommendations are relevant for human micro-
biome research, there is a need for more grounded un-
derstanding of contextual factors that may be unique to
human microbiome research in addressing what criteria
to determine returnable findings and developing ethical
practices for managing disclosure. Two survey studies
with American institutional review board (IRB) and
Canadian research ethics board (REB) chairs and vice-
chairs, respectively, found that most respondents saw a
prominent role for IRBs/REBs in defining the criteria,
circumstances, and processes by which individual gen-
etic research results should be returned to participants
and their families [57, 58]. Likewise, the roles of IRBs/
REBs, researchers, biobank personnel, and research
participants should be further deliberated in human
microbiome research to develop ethical guidelines and
practices with respect to return of results.
Conclusions
We have discussed the social and ethical challenges
associated with biobanking for human microbiome re-
search, focusing on the debate over identifiability and
ethical challenges of returning individual results and
incidental findings for clinical management. We suggest
that human microbiome research samples should be
treated with the same privacy and confidentiality safe-
guards as human tissue samples or other identifying
sources of information, not only because of the possi-
bility of re-identifying the individual donors, but also
because of the specific information about individuals
that may be encoded in microbiome-related data. How-
ever, we draw attention to circumstances in which
bacterial cultures are cultivated from these samples, but
exist separately and cannot be linked back to individual
donors; our argument of treating human microbiome
research samples as ‘human’ samples does not extend
to these cases. We also propose that returning individ-
ual results in human microbiome research can provide
a valuable clinical tool for patient care management,
but highlight the need to address how to manage the
processes ethically and consider contextual factors that
may be unique to human microbiome research.
As we have outlined in the context of probiotics and
fecal transplants, the drive for translating human micro-
biome research into practical applications requires further
understanding of how scientific, clinical, political and pub-
lic interests and concerns intersect and are negotiated. By
articulating these ethical challenges, we hope to contribute
to the discussion on the ELSI of human microbiome re-
search in ways that can foster more collaborative dialogue
between scientists, biobank personnel, research ethics
boards, and relevant regulatory agencies for ethical guid-
ance regarding the use of human microbiome research
samples and related data.
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